MDIP is a community that brings together care providers, payors, clinicians, nurses and patients to improve access to molecular diagnostics and ensure the delivery of personalised cancer care in the UK.
Scroll down to discover
To launch and build an ecosystem creating a learning environment to enable rapid translation of molecular diagnostics into routine clinical care
Support MDIP partners in all aspects of the biomarker testing pathway, including patient access, reimbursement, test selection and interpretation of results
Document and disseminate best practice in biomarker testing through the MDIP network, and beyond through publication and other media
Provide access to educational materials appropriate for medical professions and patients living with cancer
Connect with like-minded specialists, share information, overcome barriers
Learn more about precision oncology from peers and field-leaders
Define data-driven best practice through local and national networks
Evolve your practice towards personalised cancer therapy
Thank you for joining the MDIP community. Our team will get back to you with further detail.
Following the successful launch of the Molecular Diagnostic Innovation Partnership on 24 November 2020, we expect to run an exciting face-to-face conference in 2022 (Covid-19 permetting) and we are keen to hear about your own experiences and solutions in respect of embedding biomarkers into routine clinical cancer care. We kindly encourage you to review the themes we wish to explore in our first conference and complete our Abstracts and Posters Submission Form, should you be willing to share some highlights on your research and work.Discover conference themes
The patient journey
Regulation & quality
Education & outreach
Thank you for submitting your abstract. Our team will get back to you regarding the next steps.
The MDIP will run as an autonomous organisation, underpinned by collaborative partnerships between different stakeholders. Operational aspects of the MDIP will be supported by the OncoDNA MDIP team, under the leadership of the OncoDNA UK country lead. The strategic focus of the MDIP will be directed by the Strategic Advisory Board (SAB), whose recommendations will be relayed to the OncoDNA MDIP team.
The SAB will consist of 7-12 members:
• 1-2 oncologists
• 1-2 pathologists or consultant clinical scientists
• 1-2 clinical nurse specialists
• 1-2 representatives from the insurance sector
• 1-2 patient representatives
• 1-2 academic with expertise in cancer genomics (physician or scientist)
• 1 representative from OncoDNA